Cosmo Initiates Phase I Trials of CB-03-01 for the Treatment of Skin Disorders
Cosmo Pharmaceuticals announced that the Austrian Agency for Health and Food Safety [“AGES”] has authorised the commencement of a Phase I clinical study of its novel anti-androgen based cream, CB-03-01, for the topical treatment of skin disorders, including acne, alopecia and hirsutism.
Three cohorts of 8 male volunteers each will be tested, with single ascending doses at the Medical University of Vienna. The principal investigator will be Dr. Markus Müller, Department of Clinical Pharmacology at the Medical University of Vienna. Cosmo will manufacture the cream at its GMP approved facilities in Lainate, Milan, Italy.
Anti-androgens are known to be effective in controlling acne, androgenetic alopecia (androgen-induced male baldness), and hirsutism (androgen-induced facial and body hair growth in females) but, when systemically applied, they can detrimentally affect the sex life of patients. Pre-clinical studies have shown that CB-03-01 could be as active as currently marketed treatments but devoid of common systemic effects since, once absorbed, it is rapidly metabolised to a physiological substance lacking anti-androgen activity.
Commenting on today’s announcement, Mauro Ajani, CEO of Cosmo, said: “CB-03-01 is the first new chemical entity that Cosmo is developing and the only product so far that is not based on our innovative MMX™ technology. It is one of more than 20 molecules originally identified and patented by Cosmo. We are delighted to be working on this trial with the University of Vienna, which is known for its excellence in skin related diseases. CB-03-01 has the potential to be the first topically effective anti-androgen treatment on the market.”